Aeterna Zentaris (AEZS) | Financial Analysis & Statements
Aeterna Zentaris Inc. Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2024Income Metrics
Revenue
3.2M
Gross Profit
1.1M
35.04%
Operating Income
-5.1M
-160.68%
Net Income
-1.9M
-60.85%
EPS (Diluted)
$-0.64
Balance Sheet Metrics
Total Assets
68.5M
Total Liabilities
32.6M
Shareholders Equity
35.9M
Debt to Equity
0.91
Cash Flow Metrics
Operating Cash Flow
-835.5K
Free Cash Flow
-2.1M
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2024
Annual Income Flow
2023
Aeterna Zentaris Income Statement From 2020 to 2023
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 7.3M | 13.9M | 13.5M | 11.9M |
| Cost of Goods Sold | 4.3M | 5.8M | 5.3M | 5.9M |
| Gross Profit | 3.0M | 8.1M | 8.2M | 6.0M |
| Gross Margin % | 41.1% | 58.5% | 60.9% | 50.4% |
| Operating Expenses | ||||
| Research & Development | 2.1M | 1.3M | 3.0M | 1.5M |
| Selling, General & Administrative | 5.6M | 2.7M | 2.6M | 2.7M |
| Other Operating Expenses | - | - | - | - |
| Total Operating Expenses | 7.7M | 4.1M | 5.6M | 4.1M |
| Operating Income | -4.7M | 4.1M | 2.6M | 1.8M |
| Operating Margin % | -64.9% | 29.2% | 19.2% | 15.5% |
| Non-Operating Items | ||||
| Interest Income | 328.8K | 68.7K | - | - |
| Interest Expense | 96.6K | 95.8K | 119.1K | 137.4K |
| Other Non-Operating Income | 73.6K | 272.4K | 158.6K | -204.2K |
| Pre-tax Income | -4.5M | 4.3M | 2.6M | 1.5M |
| Income Tax | -900.6K | 1.0M | -52.9K | 0 |
| Effective Tax Rate % | 0.0% | 23.9% | -2.0% | 0.0% |
| Net Income | -3.6M | 3.2M | 2.6M | 1.5M |
| Net Margin % | -48.9% | 23.3% | 19.6% | 12.3% |
| Key Metrics | ||||
| EBITDA | -2.9M | 5.6M | 4.2M | 3.2M |
| EPS (Basic) | $-1.92 | $1.87 | $1.33 | $0.66 |
| EPS (Diluted) | $-1.92 | $1.87 | $1.33 | $0.66 |
| Basic Shares Outstanding | 2529968 | 2519921 | 2510615 | 2508056 |
| Diluted Shares Outstanding | 2529968 | 2519921 | 2510615 | 2508056 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Aeterna Zentaris Balance Sheet From 2020 to 2023
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Assets | ||||
| Current Assets | ||||
| Cash & Equivalents | 6.7M | 10.2M | 6.1M | 4.2M |
| Short-term Investments | - | - | - | - |
| Accounts Receivable | 126.1K | 2.1M | 1.6M | 1.6M |
| Inventory | 4.0M | 2.8M | 1.8M | 949.0K |
| Other Current Assets | - | - | - | - |
| Total Current Assets | 11.2M | 15.2M | 9.7M | 7.1M |
| Non-Current Assets | ||||
| Property, Plant & Equipment | 11.2M | 10.7M | 11.2M | 10.6M |
| Goodwill | 7.3K | 9.3K | 12.2K | 14.5K |
| Intangible Assets | 7.3K | 9.3K | 12.2K | 14.5K |
| Long-term Investments | - | - | - | - |
| Other Non-Current Assets | 823.9K | 629.9K | 823.1K | 1.2M |
| Total Non-Current Assets | 12.5M | 12.6M | 14.6M | 15.8M |
| Total Assets | 23.7M | 27.8M | 24.4M | 22.9M |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts Payable | - | - | - | - |
| Short-term Debt | 298.7K | 273.0K | 227.5K | 253.2K |
| Current Portion of Long-term Debt | - | - | - | - |
| Other Current Liabilities | - | - | - | - |
| Total Current Liabilities | 1.3M | 1.5M | 762.4K | 1.1M |
| Non-Current Liabilities | ||||
| Long-term Debt | 1.4M | 1.7M | 1.9M | 2.1M |
| Deferred Tax Liabilities | 0 | 807.5K | 0 | 685.6K |
| Other Non-Current Liabilities | - | - | - | - |
| Total Non-Current Liabilities | 1.4M | 2.5M | 1.9M | 2.8M |
| Total Liabilities | 2.7M | 4.0M | 2.6M | 3.9M |
| Equity | ||||
| Common Stock | 12.6M | 12.3M | 13.0M | 12.9M |
| Retained Earnings | 4.7M | 8.0M | 5.1M | 2.4M |
| Treasury Stock | - | - | - | - |
| Other Equity | - | - | - | - |
| Total Shareholders Equity | 21.0M | 23.8M | 21.7M | 19.1M |
| Key Metrics | ||||
| Total Debt | 1.7M | 1.9M | 2.1M | 2.3M |
| Working Capital | 9.9M | 13.6M | 9.0M | 6.0M |
Balance Sheet Composition
Aeterna Zentaris Cash Flow Statement From 2019 to 2023
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -3.6M | 3.2M | 2.6M | 1.5M | - |
| Depreciation & Amortization | 1.5M | 1.4M | 1.5M | 1.4M | - |
| Stock-Based Compensation | 195.2K | 66.1K | 14.0K | 107.3K | - |
| Working Capital Changes | 618.0K | -1.7M | -1.0M | 818.2K | 0 |
| Operating Cash Flow | -2.1M | 4.2M | 3.0M | 4.0M | - |
| Investing Activities | |||||
| Capital Expenditures | -739.3K | -286.5K | -552.1K | -485.2K | - |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -739.3K | -321.7K | -620.1K | -379.7K | -35.8K |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | -279.3K | -220.4K | -262.4K | -362.3K | - |
| Financing Cash Flow | -286.8K | -220.4K | -262.4K | -362.3K | - |
| Free Cash Flow | -3.5M | 4.6M | 2.2M | 3.0M | - |
| Net Change in Cash | -3.1M | 3.6M | 2.1M | 3.2M | -35.8K |
Cash Flow Trend
Aeterna Zentaris Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-1.95
Forward P/E
-1.70
Price to Book
0.54
Price to Sales
7.38
PEG Ratio
-1.70
Profitability Ratios
Profit Margin
41.07%
Operating Margin
-152,750.00%
Return on Equity
-81.71%
Return on Assets
-29.96%
Financial Health
Current Ratio
5.94
Debt to Equity
1.80
Beta
2.26
Per Share Data
EPS (TTM)
$-2.31
Book Value per Share
$10.68
Revenue per Share
$1.96
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| AEZS | 17.5M | -1.95 | 0.54 | -81.71% | 41.07% | 1.80 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Alnylam | 41.9B | 132.73 | 52.09 | 73.28% | 8.45% | 376.19 |
| Royalty Pharma plc | 29.4B | 27.89 | 3.29 | 13.20% | 32.42% | 92.33 |
| Insmed | 31.0B | -22.40 | 40.88 | -249.28% | -210.54% | 101.43 |
Financial data is updated regularly. All figures are in the company's reporting currency.